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Abstract
Background: Meta-analysis methods exist for combining multiple microarray datasets. However, there are a wide
range of issues associated with microarray meta-analysis and a limited ability to compare the performance of
different meta-analysis methods.
Results: We compare eight meta-analysis methods, five existing methods, two naive methods and a novel
approach (mDEDS). Comparisons are performed using simulated data and two biological case studies with varying
degrees of meta-analysis complexity. The performance of meta-analysis methods is assessed via ROC curves and
prediction accuracy where applicable.
Conclusions: Existing meta-analysis methods vary in their ability to perform successful meta-analysis. This success
is very dependent on the complexity of the data and type of analysis. Our proposed method, mDEDS, performs
competitively as a meta-analysis tool even as complexity increases. Because of the varying abilities of compared
meta-analysis methods, care should be taken when considering the meta-analysis method used for particular
research.
Background
Many researchers have embraced microarray technology.
Due to extensive usage of microarray technology, in
recent years there has been an explosion in publicly
available datasets. Examples of such repositories include
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.
nih.gov/geo/), ArrayExpress http://www.ebi.ac.uk/micro-
array-as/ae/ and Stanford Microarray Database (SMD,
http://genome-www5.stanford.edu/, as well as research-
ers’ and institutions’ websites. The use of these datasets
is not exhausted, when used wisely they may yield a
depth of information. Demand has increased to effec-
tively utilise these datasets in current research as addi-
tional data for analysis and verification.
Meta-analysis refers to an integrative data analysis
method that traditionally is defined as a synthesis or at
times review of results from datasets that are indepen-
dent but related [1]. Meta-analysis has ranging benefits.
Power can be added to an analysis, obtained by the
increase in sample size of the study. This aids the ability
of the analysis to find effects that exist and is termed
‘integration-driven discovery’ [2]. Meta-analysis can also
be important when studies have conflicting conclusions
as they may estimate an average effect or highlight an
important subtle variation [1,3].
There are a number of issues associated with applying
meta-analysis in gene expression studies. These include
problems common to traditional meta-analysis such as
overcoming different aims, design and populations of
interest. There are also concerns specific to gene expres-
sion data including challenges with probes and probe
sets, differing platforms being compared and laboratory
effects. As different microarray platforms contain probes
pertaining to different genes, platform comparisons are
made difficult when comparing these differing gene lists.
Often the intersection of these lists are the only probes
to be retained for further analysis. Moreover, when
probes are mapped to their ‘Entrez IDs’ [4] for cross
platform comparisons often multiple probes pertain to
the same gene. Due to reasons ranging from alternative
splicing to probe location these probes may produce dif-
ferent expression results [5]. Ideal methods for aggregat-
ing these probe results in a meaningful and powerful
way is currently the topic of much discussion. Labora-
tory effects are important because array hybridisation is
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array hybridisation include different experimental proce-
dures and laboratory protocols [6], sample preparation
and ozone level [7]. For more details of the difficulties
associated with microarray meta-analysis please refer to
Ramasamy et al. 2008 and other works [5,8-12].
We propose a new meta-analysis approach and provide
a comprehensive comparison study of available meta-
analysis methods. Our method, ‘meta differential expres-
s i o nv i ad i s t a n c es y n t h e s i s ’, (mDEDS) is used to identify
differentially expressed (DE) genes which extends the
DEDS method [13]. This new method makes use of mul-
tiple statistical measure across datasets to obtain a DE
list, but becomes a novel tool, with respect to DEDS with
the ability to integrate multiple datasets. Hence this
meta-method concatenates statistics from datasets in
question and is able to establish a gene list. Such integra-
tion should be resilient to a r a n g eo fc o m p l e x i t yl e v e l s
inherent in meta-analysis situations. The strength of
mDEDS as a meta-method over DEDS as a method for
selecting DE genes is highlighted by comparing these two
approaches to one another in a meta-analysis context.
Throughout this paper the statistics used within mDEDS
and DEDS are the t and modulated t statistic [14], SAM
[15], the B statistic [16] and fold-change (FC) statistic,
although any statistic can be chosen.
We also perform a comparison study of meta-analysis
methods including the Fisher’s inverse chi-square
method [17], GeneMeta [2,18], Probability of Expression
(POE) [19], POE with Integrative Correlation (IC)[ 2 0 ] ,
RankProd [21] (the latter four are available from Bio-
conductor) and mDEDS as well as two naive methods,
‘dataset cross-validation’ and a ‘simple’ meta-method.
For meta-methods with several varying parameters, we
have made use of the suggested or default options.
The performance of the different meta-analysis meth-
ods is assessed in two ways, through a simulation study
and through two case studies. For the simulation study
performance is measured through receiver operating
characteristic (ROC) curves as well as the area under
these ROC curves (AUC). The two different case studies
vary in complexity and performance are assessed through
predication accuracy in a classification framework. War-
nat et al. [22] uses validation to evaluate performance
while using multiple datasets. Our validation method dif-
fers from their process slightly. Their method takes a ran-
dom selection of samples from multiple datasets to
obtain a test and training set. We retain to original data-
sets, leaving them complete. Our method aims to simu-
late real situations where an additional dataset would
need to be classified after a discriminate rule was devel-
oped. Although within this paper mDEDS is used in a
binary setting, mDEDS is a capable multi-class meta-ana-
lysis tool, which is a concept examined by Lu et al. [23].
It is possible to consider meta-analysis at two levels,
‘relative’ and ‘absolute’ meta-analysis. ‘Relative’ meta-
a n a l y s i sl o o k sa th o wg e n e so rf e a t u r e sc o r r e l a t et oa
phenotype within a dataset [10]. Multiple datasets are
either aggregated or compared to obtain features which
are commonly considered important. Meta-methods
pertaining to this method include Fisher’s inverse chi-
square, GeneMeta, RankProd and the ‘dataset cross-vali-
dation’ meta. ‘Absolute’ meta-analysis seeks to combine
the raw or transformed data from multiple experiments.
By increasing the number of samples used, the statistical
power of a test is increased. Traditional microarray ana-
lysis tools are then used on these larger datasets. The
‘simple’ meta method is an example of ‘absolute’ meta-
analysis approach.
In this paper we will begin by describing existing
meta-analysis methods, then we will outline our pro-
posed mDEDS method. This is followed by the compari-
son study, where publicly available datasets are
combined by different meta-analysis methods, examining
their ability under varying degrees of complexity, as well
as comparing mDEDS to DEDS. Finally, we provide dis-
cussion and conclusions of results.
Existing meta-analysis methods
Let X represent an expression matrix, with i =1 ,..., I
genes and j =1 ,..., N samples. If there are k = 1,..., K
datasets, nk represents the number of samples in the kth
dataset. For simplicity, and without loss of generality, we
focus on dichotomous response; i.e., two-group compar-
isons. We designate groups as treatment T and control
C. For two-channel competitive hybridization experi-
ments, we assume that the comparisons of log-ratios are
all indirect; that is we have nT arrays in which samples
from group T are hybridized against a reference sample
R, and we can obtain nT log-ratios, MTj =l o g 2(Tj/R); j =
1, ..., nT from group T. In an identical manner nc log-
ratios are also calculated from group C. For Affymetrix
oligonucleotide array experiments, we have nT chips
with gene expression measures from group T and nC
chips with gene expression measures from group C.
Fisher’s inverse chi-square
Fisher, in the 1930 s developed a meta-analysis method
that combines the p-values from independent datasets.
One of a plethora of methods for combining the p-
values [17], is the Fisher summary statistic,
Sl o g p i
k
K
ik =−
= ∑ 2
1
() , (1)
which tests the null hypothesis that for gene i, there is
no differences in expression means between the two
groups. The p-value pik is the p-value for the ith gene
from the kth dataset. In assessing Si, the theoretical null
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K.I ti sa l s op o s s i b l et oe x t e n d
the Fisher methods by producing weights for different
datasets based on, for example, quality.
GeneMeta
One of the first methods that integrates multiple gene
expression datasets was propose by Choi et al. [2] who
describe a t-statistics based approach for combining
datasets with two groups. An implementation of this
method is found in GeneMeta[18] an R package con-
taining meta-analysis tools for microarray experiments.
Choi et al. [2] described a meta-analysis method to
combine estimated effect-sizes from the K datasets. In a
two group comparisons, a natural effect size is the t-sta-
tistics. For a typical gene i, the effect size for the kth
dataset is defined as
d
TC
S
k
kk
pk
=
−
, (2)
where Tk and Ck represent the means of the treatment
and the control group respectively in the kth study. Spk
is the pooled standard deviation for the kth dataset.
For K number of observed effect sizes, Choi et al. [2]
proposed a random effects model
dN s kk k k k =+ + md ee ,~ ( , ) 0
2
where μ is the parameter of interest, sk denotes the
within study variances and δ ~ N(0, τ
2)r e p r e s e n t st h e
between study random effects with variance τ
2.C h o ie t
al. [2] further mentioned that when τ
2 =0 ,δk denotes
the between study effect in a fixed effect model. The
random effects model is then estimated using a method
proposed by DerSimonian and Laird [24] and a permu-
tation test is used to assess the false discovery rate
(FDR).
metaArray
The R package metaArray contains a number of meta-
analysis methods. The main function is a two steps pro-
cedure which transformed the data into a probability of
expression (POE) matrix [19] and followed by a gene
selection method based on ‘integrative correlation’
(IC) [20].
Given a study, the POE method transforms the
expression matrix X to a matrix E that represents the
probability of differential expression. Each element in
the matrix Eij is defined as the chance of multiple condi-
tions present across N samples within gene i. The trans-
formed matrix, E,c o n s i s t so ft h r e ev a l u e s- 1 ,0 ,1t h a t
represent the conditions ‘under-expressed’, ‘not differen-
tially expressed’ and ‘over-expressed’. After the transfor-
mation into a POE matrix, genes of interest are
established using IC [20]. Notice that this integrative
correlation method is not restricted to be used with a
POE matrix. The method IC begins by calculating all
possible pairwise Pearson correlations (r(,’ ) ii
k ,w h e r ei ≠
i’) between genes (i and i’) across all samples within a
dataset k. Thus, we generated a pairwise correlation
matrix P with R
I = () 2 rows representing the number of
pairwise correlation and K columns representing the
number of datasets.
For a selected pair of datasets k and k’, let us denote
r
k and r
′ k as means of the correlations per study.
Gene-specific reproducibility for gene i is obtained by
only considering comparisons that contain the ith gene.
That is
Ik k ii i
kk
ii
kk
i
I
() ( ) ( ) . (,) (,) ′ =−− ′′
′′
′= ∑ rr rr
1
(3)
where i ≠ i’. When more than two datasets are being
compared, all integrative correlations for a particular
gene are aggregated. This method provides a combined
ranking for genes across K datasets.
In this comparison study, two metaArray results are
used. Distinction will be made between them using the
terms ‘POE with IC’ and ‘POE with Bss/Wss’ to indicate
what type of analysis was performed after the construc-
tion of the POE matrix.
RankProd
RankProd is a non-parametric meta-analysis method
developed by Breitling et al. [21]. Fold change (FC) is
used as a selection method to compare and rank the
genes within each dataset. These ranks are then aggre-
gated to produce an overall score for the genes across
datasets, obtaining a ranked gene list.
Within a given dataset k, pairwise FC (pFC) is com-
puted for each gene i as
TCTC T C nn TC 11 12 11 /,/,, / … (4)
producing nT × nC pFCl,m values per gene with l =
1, ..., nT and m =1 ,..., nC. The corresponding pFC ratios
are ranked and we may denote this value as pFC(i;r),
where i =1 ,..., I represents the number of genes and
r =1 ,..., R represents the number of pairwise compari-
sons between samples. Then the rank products for each
gene i is defined as
RP pFC R
i
r
R
k
K
irk =
= = ∏ ∏ () . ()
1 1
1
(5)
Expression values are independently permuted B times
within each dataset relative to the genes, the above steps
are repeated to produce RPi
b () where b = 1, ..., B.A
reference distribution is obtained from all the RPi
b ()
values, and the adjusted p-value for each of the I genes
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future analysis.
Naive meta-methods
Two forms of naive meta-methods are used in the com-
parison study. The ‘simple’ meta-method takes the
microarray expression matrices and simply combines
the datasets together, forming a final matrix made up of
all samples with no expression adjustment. The ‘dataset
cross-validation’ meta-method takes one datasets and
applies the analysis, these results are then used by the
other dataset(s) with the expectation that the results will
be transferable. In a classification context this means
that one dataset is used for feature selection and devel-
opment of the discriminant rule and we predict the out-
come of the other dataset(s) via this rule.
Method
Algorithm - mDEDS
’Meta differential expression via distance synthesis’
(mDEDS) is a meta-analysis method that makes use of
multiple statistical measures to obtain a DE list. It is
aided by ‘Differential Expression via Distance Synthesis’,
DEDS [13] which is designed to obtain DE gene lists.
Example DE measures include standard and modulated-
t stat [14], fold change, SAM [15] and the B-statistic,
amongst many others. The concept behind the proposed
meta-method considers that truly DE genes should be
selected regardless of the platform or statistic used to
obtain a DE list.
T h et r u eD Eg e n e ss h o u l ds c o r eh i g h l yw i t h i nas e to f
non-dominated genes, both within a dataset using DE
measures and also between datasets when the same DE
measures are used on different datasets across different
platforms. Consistently high ranked genes are then con-
sidered DE via mDEDS. This method endeavours to be
robust against both measure specific bias, when different
measure produce significantly different ranked lists, and
platform specific bias where particular platforms produce
results that are more favourable to particular gene sets.
1. Let there be k =1 ,. . . ,K datasets and g = 1, ..., G
appropriate (DE measuring) statistics, hence there
will be K × G statistics for each of the i = 1, ..., N
genes. Let tikg be the statistic for the ith gene, from
the kth dataset for the gth DE measure. Assuming
large values indicate increased DE genes, let the
observed coordinate-wise extreme point be
Et t t
i
i
i
iG
i
iKG 01 1 1 =…… ( ( ), , ( ), , ( )). max max max (6)
2. Locate the overall (observed, permutation)
extreme point E:
(a) Each of the K datasets is permuted B times by
randomly assigning nT arrays to class ‘T’ and nC
arrays to class ‘C’, producing b = 1,... B sets of K
datasets. For each permuted datasets the G num-
ber of DE statistics are recalculated yielding tikd
b .
Obtain the corresponding coordinate-wise maxi-
mum:
Et t t bi
b
iG
b
iKG
b
ii i
=…… ( ( ), , ( ), , ( )). max max max 11 1 (7)
(b) Obtain the coordinate-wise permutation
extreme point Ep by maximizing over the B per-
mutations,
EE E E p
b
b
b
bG
b
bKG =…… ( ( ), , ( ), , ( )). max max max 11 1 (8)
(c) Obtain E as the overall maximum: E =m a x
(Ep,E 0).
3 .C a l c u l a t ead i s t a n c ed from each gene to E. For
example, one choice for a scaled distance is
d
tikg Ekg
tikg
i
g
G
k
K
=
−
= = ∑ ∑
()
()
,
2
2
1 1 MAD
(9)
where MAD is the median absolute deviation from the
median. Order the distances, d(1) ≤ d(2) ≤ ... ≤ d(N).
Batch correction can be performed by mDEDS, by
substituting datasets with ‘batch groups’ (see
Discussion).
Comparison study
Eight meta-analysis methods are compared using a
simulated dataset and two cases studies comprising of
six publicly available datasets, pertaining to three breast
cancer and three lymphoma datasets. The purpose of
the comparison study is to establish how these meta-
analysis methods perform under varying degrees of data-
set complexity. Dataset complexity refers to the level of
difficulty present when combining multiple datasets. For
example datasets being produced on the similar plat-
forms (for example different Affymetrix platforms) are
less complex to analyse via meta-analysis then when
analysing results across very different platforms. For this
comparison paper two levels of dataset complexity are
considered. Case study 1, implemented by the breast
cancer data contains datasets from identical Affymetrix
chips, this is considered ‘similar platform meta-analysis’.
Case study 2 which makes use of the lymphoma datasets
contains samples that are hybridised using long oligo
Campain and Yang BMC Bioinformatics 2010, 11:408
http://www.biomedcentral.com/1471-2105/11/408
Page 4 of 11two colour platforms, Affymetrix chips and the ‘Lym-
phochip’ [ 2 5 ] ,t h i si sc o n s i d e r e d‘disparate platform
meta-analysis’.
For the publicly available data, probe sets for each
platform are mapped to the relative ‘Entrez IDs’ [4].
Where multiple probes pertained to the same gene the
mean gene expression level is used. Probes with
unknown ‘Entrez IDs’ are discarded. Only the intersec-
tion of platform gene lists are used in further analysis.
Data is imputed using KNN imputation with k = 10.
Data analysis performed using R.
Performance assessment
Assessing the performance of different meta-analysis
methods is important to evaluate and compare methods.
Although important, performance assessment of meta-
analysis methods is non-trivial. Typically meta-analysis
methods will be evaluated using pre-published gene lists
and noticing the concordance of the obtained DE gene
list and published material, this process however is sub-
ject to publication bias. To avoid such biases two forms
of performance assessment will be applied in this paper.
1. Receiver operating characteristic curves (ROC):
For the simulated data where the ‘true’ DE gene list
is known, meta-analysis performance is measured via
ROC curves. ROC curves are created by plotting the
true positive rates verses the false positive rates for
the obtained DE genes. Performance is indicated by
how close the plots are to the upper left hand corner
of the ROC space. The AUC is also used as a com-
parison tool, with AUC values close to one indicat-
ing an accurate DE list. Because of the design of the
simulation study the ‘cross-validation’ meta-analysis
method can not be used.
2. Prediction accuracy: For the case studies, predic-
tion accuracy under a classification framework is
used to asses performance of the DE list. We will
use the term DE list for the consistency of this
manuscript, although strictly speaking in a classifica-
tion framework such gene lists are known as feature
gene lists. To classify within the case studies, each
consisting of three independent datasets, two data-
sets are combined via the meta-analysis methods
and DE genes are selected. When DE gene selection
is not part of the meta-analysis approach DE genes
are ranked via ‘between sum of squares over within
sum of squares’ Bss/Wss [26]. Using these two data-
sets, a discriminant rule is constructed by diagonal
linear discriminant analysis (DLDA) [26]. The third
independent dataset is classified using this rule. The
ability for the meta-analysis method to collaborate
information from the two distinct datasets is
reffected in the ability to classify the third. Predic-
tion accuracy is used because the ‘true’ DE list is not
known. In these case studies, performance can only
be judged relative to the other compared methods.
Simulation study
To evaluate the performance of the different meta-ana-
lysis methods, data was simulated to represent three
separate gene expression datasets. The simulation
approach is adapted from an approach presented by
Ritchie et al. [27]. A non-parametric bootstrap simula-
tion is used where a matrix of non-differentially
expressed gene expression data is sampled from three
different datasets. This ‘background’ noise contains the
latent characteristics of an actual microarray data yet
contains no biologically DE genes. Samples are con-
structed with replacement from the original data, such
that an even binary class distribution is established.
DE genes are simulated via a 2 fold increase in fold
change. Two types of DE genes are simulated, ‘true’ DE
genes, and ‘platform specific’ DE genes. ‘True’ DE genes
are identical genes within each dataset, representing bio-
logically relevant DE genes. ‘Platform specific’ DE genes
simulate platform bias apparent within DE genes from
microarray experiments [28] and are randomly selected
from the genes in the datasets, with the exclusion of the
‘true’ DE genes. This simulation taps into the important
notion that a powerful meta-analysis tool will have the
ability to correctly distinguish a true DE gene which is
DE across multiple platforms from a DE gene which is
simply a platform phenomena.
Case study 1 - Breast cancer: Similar platform meta-
analysis
Three publicly available Affymetrix datasets are used for
the breast cancer study, all three datasets use the affy-
metrix platform U133A. Classification of the breast can-
cer samples aims to distinguish between the sample’s
estrogen receptor (ER) status (+ve or -ve) as determined
by the sample information provided with the datasets,
we refer readers to the original manuscripts for more
details regarding this status. In this case ER status is
being used simply as a response variable common
throughout all considered datasets, it should be under-
stood that predicting ER status using gene expression
data is not the same as immunohistochemistry. These
datasets include the Farmer et al. dataset [29]
(GSE1561) which utilises the Affymetrix U133A plat-
form with 49 samples, comprising of 27 +ve and 22 -ve
samples. The Loi et al. dataset [30] contains Affymetrix
samples from three platforms, U133 (A,B) and U133plus
some of which underwent treatment and some which
did not. Samples from platform U133A which did not
experience any treatment are used in this study, which
totalled 126 with 86 +ve and 40 -ve samples (GSE6532).
Ivshina et al. [31], developed breast cancer samples on
Affymentrix U133A arrays, 200 in total corresponding
to 49 +ve and 151 -ve samples (GSE4922). The
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a ‘similar platform meta-analysis’ context was assessed
via classification. The Farmer et al. and Ivshina et al.
datasets were combined via meta-analysis and used to
obtain a DE gene list and construct a classification
model. The Loi et al. dataset was classified using this
gene list and discriminant rule.
Case study 2 - Lymphoma: Disparate platform meta-
analysis
An original lymphoma dataset was obtained from the
Department of Haematology and Stem Cell Transplant at
St Vincent’s Hospital Sydney (which will be referred to as
SVH). Gene expression levels have been gathered from
60 patients presenting with lymphoma cancers, 37 of
these samples are Follicular Lymphoma (FL) and 23 sam-
p l e sa r eD i f f u s eL a r g eB - C e l lL y m p h o m a( D L B C L ) .
Human 19000 oligo array slides from the Adelaide
microarray consortium were used to obtain microarray
expressions. Two well known publicly available datasets
were also analysed. The Shipp et al. data [32] contains 19
FL and 58 DLBCL samples, hybridised using the Affyme-
trix platform HU6800. Alizadeh et al. [25] also contains
19 FL samples and 27 DLBCL samples, hybridized to the
‘Lymphochip’ which is a custom designed cDNA micro-
array. The performance of the meta-analysis methods
employed in a ‘disparate platform meta-analysis’ context
was also assessed via classification. The Shipp et al. and
Alizadeh et al. datasets were combined via meta-analysis
and used to obtain a DE gene list as well as construct a
classification model. The SVH dataset was classified
using this gene list and classification rule.
Case study 3 - mDEDS versus DEDS
To establish the success of mDEDS as a meta-analysis
method beyond the capabilities of DEDS, DEDS and
mDEDS are compared. The strength of DEDS comes from
its ability to synthesise results from a range of statistics,
mDEDS goes beyond this to consider results from a range
of statistics across multiple datasets. DEDS is a method for
selecting DE genes and to this end was used in the simple
meta-method described in the ‘Existing meta-analysis
methods’ section. Datasets from both the breast cancer
study and the lymphoma study were used in the compari-
son of these meta-methods with the Loi et al. and the
SVH datasets used as the independent test sets.
Results
Simulation
Three datasets were simulated, with 150, 100 and 80
samples, each with 20000 genes. The percentage of DE
genes varied between 2.5%, 4% and 10%, with half the
DE genes on each platform being ‘true’ and the other
being ‘platform specific’ DE genes. Figure 1 shows the
ROC curves for 5% true and 5% platform specific DE
genes. These results are indicative of all considered DE
percentages. Table 1 contains the AUC values for the
three different DE gene percentage levels for the differ-
ent meta-analysis methods. GeneMeta, RankProd, POE
with Bss/Wss and POE with IC appear to struggle with
obtaining an accurate ‘true’ DE list. Fisher and mDEDS
perform competitively with the difference between
Fisher, simple and mDEDS reducing as the number of
genes in the gene list increases.
Case study 1 - Breast cancer: Similar platform meta-
analysis
Figure 2 displays the error rates for the classification of
the Loi et al. dataset, the number of DE genes used to
build the classification model varies across the horizon-
t a la x i s .T h em e a ne r r o rr a t e sc a nb ef o u n di nT a b l e2 .
The majority of the applied meta-methods successfully
Figure 1 ROC curves for simulation. ROC curves for differing
meta-analysis methods. GeneMeta, RankProd, POE with Bss/Wss and
POE with IC appear to struggle with obtaining an accurate ‘true’ DE
list, Fisher and mDEDS perform competitively.
Table 1 AUC values for simulated and dataset analysis
AUC
Meta-method 2.5% 4% 10%
Fisher 0.996 0.993 0.982
POE with Bss/Wss 0.489 0.490 0.487
POE with IC 0.483 0.492 0.491
GeneMeta 0.861 0.866 0.876
RankProd 0.999 0.998 0.834
Simple 0.998 0.998 0.994
mDEDS 0.998 0.998 0.994
The AUC values for the simulated datasets, for each meta-analysis method. DE
genes are simulated at 2.5%, 4% and 10% levels, with half the genes being
‘true’ DE genes and the other half being ‘platform specific’ DE genes
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forms to distinguish between the binary classification of
positive and negative ER status, with the notable excep-
tions of GeneMeta and the simple meta-method. Both
POE methods become more reliable meta-methods as
the number of genes used to build the classifier
increases. RankProd, Fisher, the cross-validation meta-
method and mDEDS produce consistently relatively low
classification errors for this similar platform analysis.
When Farmer et al. and Ivshina et al. were used as the
independent test sets, results from the meta-analysis
methods were similar (results not shown).
Case study 2 - Lymphoma: Disparate platform meta-
analysis
Figure 3 shows the error rates for the prediction of the
SVH dataset. This study examines the different meta-
methods across highly varying platforms (both cDNA
and Affymetrix). The Fisher’s inverse chi-square and
POE with IC meta-methods perform well under such
conditions, conversely GeneMeta, POE with Bss/Wss
and RankProd appear to struggle in DE gene selection.
However, mDEDS can still utilise these different experi-
ments purposefully, producing the lowest mean error
rate (Table 3), and a very competitive classifier. When
Shipp et al. and Alizadeh et al. were used as the inde-
pendent test sets, results from the meta-analysis meth-
ods were similar (results not shown).
Case study 3 - mDEDS versus DEDS
Table 4 shows the mean error rates of the breast cancer
and the lymphoma datasets when classified using
mDEDS and the simple meta-method with DEDS as the
method for selecting DE genes. It is apparent from this
table that DEDS is not capturing the DE genes across
the multiple datasets to distinguish the two classes
being compared, although mDEDS is acting as a suc-
cessful meta-method.
Discussion
The simulation study coupled with the two cases studies
of varying meta-analysis complexity offers insight into
the eight meta-analysis methods compared in this paper.
It is important to validate meta-analysis methods,
although at times this is difficult to perform. Some
meta-methods are simple variants of common classical
statistical methods, others offer more sophisticated
Figure 2 Breast cancer classification. Plots of error rates in the binary classification of three breast cancer datasets as the number of genes
used to build the classifier varies from 10 to 500. Classification error rates are displayed for the 8 different meta-analysis approaches. Plots are
split into two sub-plots for reading ease, mDEDS appears in both for comparative purposes.
Table 2 Breast cancer classification error rates
Meta-Method Mean Error
Fisher 0.182
POE with Bss/Wss 0.257
POE with IC 0.199
GeneMeta 0.534
RankProd 0.182
Simple 0.314
Cross-Validation 0.186
mDEDS 0.174
Mean of error rates in the binary classification of three breast cancer datasets
using DLDA
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environment. A large proportion of meta-research deals
with DE genes and the process of obtaining a DE list
from multiple datasets. Unfortunately DE gene lists are
illusive because the biological DE gene lists are not
known. Often for validation purposes DE lists are com-
pared to other published DE lists with the level of con-
gruency indicative of the success of the meta-method.
This method suffers from publication bias [26] as one is
continuously publishing pre-published information, with
little validation to the variations that are occuring. An
alternative assessment criteria utilizing the classification
framework offers an intuitive validation process with
interpretable results. Classification performance relies
heavily on the accuracy of the classifier’s feature list,
which is traditionally taken from the DE list. Within this
meta-analysis study independent dataset validation
classification was performed, using DLDA. DLDA was
chosen as Dudoit et al. [33] found that DLDA was an
effective, efficient and accurate classifier for microarray
data. This study could have been conducted using any
number of classifier s provided feature selection is not
performed implicitly by the classifier. The varying DE
list obtained from the meta-methods are the only vary-
ing component in the comparison. Therefore a reduc-
tion in classification error can be attributed to the meta-
method.
Meta-analysis offers a way to enhance the robustness
of microarray technology. The ‘dataset cross-validation’
meta-analysis approach observed within this study
encapsulates a very real problem with microarrays; gene
lists selected from one platform or study have a limited
ability to be transfered. This is highlighted by their
inability to be used to classify samples generated by
another platform or study, as demonstrated by the
61.7% error rate obtained via this method (Table 3). For
both the breast cancer and lymphoma case studies some
Figure 3 Lymphoma cancer classification. Plots of error rates in the binary classification of three lymphoma cancer datasets as number of
feature used in classification varies from 10 to 500. Classification error rates are displayed for the 8 different meta-analysis approaches. Plots are
split into two sub-plots for reading ease, mDEDS appears in both for comparative purposes.
Table 3 Lymphoma cancer classification error rates
Meta-Method Mean Error
Fisher 0.276
POE with Bss/Wss 0.375
POE with IC 0.301
GeneMeta 0.525
RankProd 0.475
Simple 0.617
Cross-Validation 0.329
mDEDS 0.277
Mean of error rates in the binary classification of three Lymphoma datasets
using DLDA.
Table 4 mDEDS versus DEDS
Meta-Method Breast cancer study Lymphoma study
Mean error Mean error
Simple meta with DEDS 0.441 0.617
mDEDS 0.174 0.277
Mean of error rates when comparing mDEDS to the simple meta-methods
when DEDS is used as a feature selection method. Performance is assessed in
the binary classification of the breast cancer and lymphoma datasets using
DLDA.
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Page 8 of 11meta-analysis approaches were able to increase the
accuracy of cross platform classification, at times the
error reduced by as much as 33% which can be seen in
Table 3. This indicates that the added power through
meta-analysis produces more robust and reliable results,
eventuating in a gene list that is not platform dependent
but truly indicative of the disease.
Cross platform meta-analysis multiplies the level of
complexity in this particular analysis paradigm. The
meta-analysis complexity is suggestive of the meta-
method one should employ. Within this study we have
used two levels of meta-analysis complexity, (i) when
meta-analysis is performed across similar platforms, for
example Affymetrix with Affymetrix, (ii) when meta-
analysis is performed across disparate platforms, for
example Affymetrix with oligo arrays.
The breast cancer case study uses datasets from three
identical Affymentrix platforms. Affymetrix’sd e v e l o p -
ment and processing protocols offer a reduced variabil-
ity in array comparison [34]. This feature of Affymetrix
arrays is highlighted with the success of the cross-valida-
tion meta-analysis method, producing a relatively low
mean error rate within the breast cancer study. In this
case POE with both Bss/Wss and IC,F i s h e r ’si n v e r s e
chi-square and RankProd were able to classify competi-
tively, hence they are able to highlight between dataset
DE genes. RankProd’s success in this circumstance is
similar to the findings by Hong et al. [3] where Rank-
Prod is shown to be powerful in both simulated and
Affymetrix based meta-analysis studies.
The lymphoma case study aims to distinguish between
FL and DLBCL subtypes and the datasets used makes
this analysis more complex. Both cDNA and oligonu-
cleotide arrays are compared. These platforms vary
remarkably with differences ranging from probe length
to the presence of reference samples. As the complexity
of the meta-analysis rises POE with Bss/Wss,G e n e M e t a
and RankProd struggle to obtain a gene list robust
enough for cross platform classification. Two different
reasons could attribute to the depletion in accuracy of
the meta-methods as the level of complexity increases.
The meta methods could be over-fitting the data, meth-
ods that model the data are particularly susceptible to
this, for example GeneMeta. Conversely, some feature
selection methods may not capture the complexity of
the data, this is potentially occuring in the POE with
Bss/Wss case. Fisher’s inverse chi-square meta approach
does not take into consideration the actual intensities of
each spot on the microarray, albeit at times this method
is ideal, for example when individual intensities are
unknown, or when the characteristics of the study vary
greatly [35]. This particular characteristic of Fisher’s
inverse chi-Square method is highlighted by the more
complex lymphoma case study producing lower relative
classification errors than when used in similar platform
breast cancer analysis.
Within both complexity environments mDEDS is able
to perform DE analysis well, as this method makes use
of the different datasets but does not try to fit a full
parametric model to the data. Our proposed mDEDS
uses multiple statistical measures while developing its
ordered gene list. Using multiple measures aids robust-
ness as more of the variability can be encapsulated
within the meta-method. The success of mDEDS over
DEDS as a meta-method highlights that the method of
combining different statistics across datasets aids in the
meta-analysis process. It is possible that the multiple
platforms and multiple measures draw enough diversity
to begin to transcend cross platform variability and pro-
duce a reliable gene list. The variation in some of the
meta-method’s abilities within classification suggests
that different tools are beneficial depending on the
researcher’s current meta-analysis project.
One may speculate that mDEDS can be used in a
batch correction context. Batch effect is a term given to
non-biological experimental variation that occurs
throughout an experiment. In most cases batch effects
a r ei n e v i t a b l ea sn o n - b i o l o g i cal variations are observed
simply through multiple, apparently identical, amplifica-
tion and hybridisation. Staggering ones hybridisation
process is a practical reality of microarray experiments
for two main reasons: (i) data is often prospective and
may be collected and processed in stages, (ii) there is a
limit to the number of samples that may be amplified
and hybridised at one time [36] hence forcing batches
to form. As a result, powerful batch correction methods
are vital for microarray research. One could consider
batches obtained separately with time delays, for exam-
ple a year, as separate batches, which resemble indivi-
dual datasets on similar platforms. By using mDEDS
one can borrow strength from the multiple batches yet
avoid particular batch bias.
There are still many open questions within the meta-
analysis paradigm. For example questions pertaining to
mismatched probe sets across platforms and the hand-
ling of multiple probes for the same genes. More
research within these areas would greatly aid meta-ana-
lysis for microarrays and ones ability to make use of the
current plethora of information laying dormant in these
public repositories. However, once more of these type of
tools for meta-analysis have been developed, meta-analy-
sis will save time, money and scientific resources.
Conclusion
We compared eight meta-analysis methods, which com-
prise of five existing methods, two naive approaches and
our novel approach, mDEDS. Integrating datasets within
microarray analysis has copious and clear advantages.
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methods are more successful in their approach by com-
paring multiple meta-analysis methods, including the
Fisher’s inverse chi-square, GeneMeta, POE with Bss/
Wss, POE with IC, RankProd, a ‘dataset cross-validation’
meta and a ‘simple’ meta.
Our proposed method; mDEDS, has performed com-
petitively and at times better than currently available
meta-analysis methods. ROC curves were used as a
comparison in a simulated study and prediction accu-
racy within classification was used as an evaluation tool
in two real biological case studies. These case studies
differ in complexity regarding data being combined, the
first demonstrating the combining of three datasets
from similar platforms (different Affymetrix chipsets)
and the second combining datasets from Affymetrix,
cDNA and the Lymphochip.
In both classification comparisons mDEDS was used
as a feature selection method and produced capable
classifiers, with all else held constant. These results,
coupled with results from the simulated data, are indica-
tive of mDEDS being used as a powerful meta-analysis
method for cross laboratory and platform studies.
Availability and requirements
The R code for mDEDS is an additional feature within
the DEDS package available at http://Bioconductor.org.
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